HIV prevention therapy likely to become cheaper but accessibility concerns remain | India News – Times of India
US pharma giant Gilead Sciences’ partnership with domestic companies to produce generic versions of its groundbreaking HIV prevention therapy, lenacapavir, is expected to make treatment significantly more affordable, with prices likely to drop to a fraction of those charged in the US. However, despite this potential for reduced costs, concerns persist regarding accessibility in high-incidence…